AKS-452
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Protein subunit |
| Clinical data | |
| Routes of administration | Intramuscular |
| Identifiers | |
| CAS Number | |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
|
Medical response |
|
.svg.png){kind=small} COVID-19 portal |
AKS-452 is a COVID-19 vaccine candidate developed by Akston Biosciences.[2][3]
References
- ↑ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
- ↑ "Anti-COVID19 AKS-452 – ACT Study (ACT)". ClinicalTrials.gov. 23 December 2020. NCT04681092. Retrieved 21 March 2021.
- ↑ "A study to assess the safety and immunogenicity of Anti-COVID-19 AKS-452 vaccine for SARS-Cov-2 infection in Indian healthy subjects". ctri.nic.in. 11 October 2021. CTRI/2021/10/037269. Retrieved 11 October 2021.
| Development | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Classes | |||||||||||
| Administration | |||||||||||
| Vaccines |
| ||||||||||
| Inventors/ researchers | |||||||||||
| Controversy | |||||||||||
| Related | |||||||||||
| |||||||||||
Categories:
Hidden categories:
- Articles with short description
- Short description matches Wikidata
- Use dmy dates from December 2021
- Short description is different from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a vaccine
- All stub articles
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.